View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
December 18, 2019updated 12 Jul 2022 11:59am

LEO Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal trials

Anti-interleukin-13 is in development for the treatment of moderate-to-severe atopic dermatitis.

By GlobalData Healthcare

LEO Pharma recently announced that its anti-interleukin-13 (IL-13) biologic therapy met all its primary and secondary endpoints across three pivotal Phase III studies as part of the company’s ECZTRA trial series. 

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The drug is in development for the treatment of moderate-to-severe atopic dermatitis, tralokinumab. The announcement came on 11 December 2019. 

LEO Pharma is likely to file for approval in 2020, and tralokinumab is expected to be the first biologic treatment in the atopic dermatitis space to challenge Sanofi and Regeneron’s Dupixent (dupilumab), which quickly solidified its place as the gold standard of therapy since its approval in the US in 2017. 

Over the next decade, GlobalData anticipates that Dupixent will remain the most prescribed atopic dermatitis biologic, with global 2027 sales of $5.3bn, but will see noticeable competition from tralokinumab, which is expected to generate global 2027 sales of $1.6bn.

Although no study results have been published yet, tralokinumab demonstrated significant efficacy compared to placebo in Phase IIb trials with 42.5% of patients in the 300mg dose patient arm achieving a minimum improvement of 75% in the Eczema Area and Severity Index (EASI75), compared to 15.5% of patients in the placebo group. 

Across the Phase III ECZTRA 1, ECZTRA 2, and ECZTRA 3 studies, a total of 2210 participants were enrolled in randomised, double-blinded trials testing the efficacy and safety of tralokinumab against placebo. 

ECZTRA 3 also tested the efficacy and safety of the drug in combination with topical corticosteroids (TCS) to replicate the treatment regimen that moderate-to-severe atopic dermatitis patients often follow in the clinic. 

The primary endpoints for the studies were the proportion of patients achieving an Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) at Week 16, and the proportion of patients achieving EASI75 at Week 16. The secondary endpoints consisted of a proportion of patients achieving improvements across the Scoring Atopic Dermatitis (SCORAD) scale, pruritus Numerical Rating Scale (NRS), and Dermatology Life Quality Index (DLQI). 

Each trial lasted for 52 weeks and consisted of six treatment arms:

  1. Tralokinumab treatment period until Week 16, followed by tralokinumab maintenance regimen A
  2. Tralokinumab treatment period until Week 16, followed by tralokinumab maintenance regimen B
  3. Tralokinumab treatment period until Week 16, followed by a placebo maintenance regimen
  4. Placebo treatment period until Week 16, followed by a placebo maintenance regimen
  5. Tralokinumab treatment period until Week 16, followed by an open-label tralokinumab maintenance regimen
  6. Placebo treatment period until Week 16, followed by an open-label tralokinumab maintenance regimen

LEO Pharma’s announcement comes at the end of a busy year for the atopic dermatitis pipeline. 

Earlier this year, Pfizer shared positive results from two Phase III studies for its first-in-class Janus kinase (JAK) inhibitor abrocitinib, and Dermira announced that it had been granted Fast Track designation by the Food and Drug Administration (FDA) due to positive data from its Phase IIb trial. 

Phase III trials for lebrikizumab have begun, posing a challenge to LEO Pharma’s tralokinumab as they are both anti-IL-13 biologics. However, because lebrikizumab is set to enter the atopic dermatitis space after tralokinumab, GlobalData expects that lebrikizumab will only earn global 2027 sales of $617m. With such a dynamic late-stage pipeline, the future of the atopic dermatitis market looks to be very competitive.

Related Reports

GlobalData (2018) Atopic Dermatitis – Market Analysis and Forecasts to 2027, November 2018, GDHC172PIDR

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena